M a te r ia ls and M eth o d s: A to ta l of 50 p a tie n ts w ith B P H w ere random ized to receive e ith e r lo w e r en erg y tr a n s u r e th r a l m icro w ave th erm o th erap y tre a tm e n t (P ro sta so ft 2.0)* or placebo tre a tm e n t an d fo llo w ed fo r 26 w eeks a fte r tre a tm e n t. A ll p atien ts com pleted a M ad sen sym ptom score and q u a lity o f life q u e stio n n a ire to assess a ccep tab ility, d a ily a c tiv itie s , psychological w ell-being, so cial a c tiv itie s an d im p ro vem en t in q u a lity of life . A sexual function q u estio n n aire w a s used to assess changes in sexu al fu n ctio n a fte r m icrow ave therm otherap y.
R e s u lts : A s ig n ific a n t d ifferen ce in vo id in g p aram eters and symptom score w as found betw een th e tr a n s u re th r a l m icro w a ve th e rm o th e ra p y and sham groups. M axim um uroflow changed from 9.6 m l. p er second a t b a se lin e to 13.9 m l. p er second and from 9.9 m l. per second a t b aseline to 9.6 m l. p er second a t 26 w eeks for tra n s u r e th r a l m icrow ave th erm o th erap y and sham groups, re s p e c tiv e ly . M a d se n score im p ro ved from 13.2 to 5.3 for th e tra n s u re th ra l m icrow ave therm o th e ra p y group and from 11.9 to 9.1 fo r th e sham group. F o r q u a lity of life m easures, a s ta tis tic a lly s ig n ific a n t d ifferen ce in fa v o r o f th e tra n s u re th ra l m icro w ave th erm o th erap y group w as found o n ly for th e a c c e p ta b ility item . A t b a se lin e and a fte r 26 w eeks no s ta tis tic a lly sig n ifican t d ifferen ce w a s observed b etw een th e 2 groups fo r Q u a lity of L ife m easures docum enting sexual fu n ctio n . H o w e ve r, alm o st 2 0 % of p a tie n ts tre a te d by e ith e r tra n s u re th ra l m icrow ave therm o th e ra p y or sham cla im e d a t 26 w eeks a fte r tre a tm e n t th a t tre a tm e n t had influenced sexual fu n ctio n .
C o n clu sio n s: A lth o u g h s ig n ific a n t changes in objective and subjective param eters w ere found in p a tie n ts a fte r lo w e r en erg y m icro w ave th e rm o th e rap y, the change in q u a lity of life w as m in im a l. In a d d itio n to th e m in im a l in v a s iv e n e ss o f tra n s u re th ra l m icrow ave therm otherap y, p re s e rv a tio n o f se x u al fu n c tio n is ap p ealin g . Although benign prostatic hyperplasia (B P H ) can lead to serious complications in some patients1 the m ajority of pa tients seeldng medical attention do so because of bothersome symptoms that affect the quality of their lives. The decision to treat a patient is based largely on the extent to which symptoms interfere w ith daily activities.2 Individual patient views of bother w ill va ry significantly, and so the degree of symptom severity is im portant in overall patient outlook. Consequently selection of treatm ent is based prim arily on individual view of benefit (symptoms improvement) versus risk.
Transurethral prostatectomy has become w ell established as standard surgical technique for B P H unless the prostate gland is too large.3'4 This standard has been challenged in recent years by several alternative treatments for B P H . B e sides being less invasive w ith decreased need for anesthesia, a considerably lower morbidity and m ortality rate is claimed for alternative treatments. Transurethral microwave ther motherapy has engendered great enthusiasm as alternative m inim ally invasive treatm ent for patients w ith B P H . Trans urethral microwave thermo therapy uses a combination of transurethrally administered radiating heat energy and con ductive cooling administered via the urethra. Treatment re sults in high power microwave application deep in the lateral lobes, leading to irreversible cell damage of prostatic tissue without damaging the urethra. The effectiveness of treat ment has not surpassed that of transurethral prostate resec tion ,5
Before treatment patients appear to have different symp tom severity and health status.6 Moreover, we suggest that alternative treatments have a different impact on changes in quality of life than transurethral prostatectomy in patients w ith B P H . This explains why the development of a B P H specific health related quality of life outcome measure is an essential requirement to allow time related comparison among treatments for B P H .7 Demand for m inim ally invasive medical care by increasing numbers of younger, less symp tomatic and sexually active male patients needs our atten tion. Nothing is known about the effect on quality of life after thermo therapy. In our study changes in quality of life and in sexual function were evaluated in patients participating in a placebo controlled transurethral microwave thermotherapy study. 1839
QUALITY OF LIFE ASSESSMENT IN PATIENTS TREATED WITH LOWER ENERGY THERMOTHERAPY MATERIALS AND METHODS
From June 1991 through December 1992, 50 men 50 to 79 years old with symptoms of B P H were randomized to receive transurethral microwave thermotherapy or sham treatment. Patients were included according to age 45 years old or older, duration of symptoms 3 months or longer, Madsen symptom score 8 points or higher, prostate volume 30 cm.0 or greater and peak uroflow less than 15 ml. per second. M ajor exclu sion criteria were prostatic carcinoma, neurogenic bladder dysfunction, history of prostate surgery and isolated enlarge ment of middle lobe. For this study we used the lower energy thermotherapy protocol (Prostasoft 2.0).* Screening included general history, complete physical ex amination, blood biochemistry (including prostate specific antigen) and urine examination (including cytology). Sever ity of symptoms was rated according to Madsen symptom score.8 A ll patients were asked to complete a quality of life and sexual function questionnaire.
Patients were randomized after informed consent was ob tained. Procedure for transurethral microwave thermotherapy has been described elsewhere.9*10 I f the patient was randomized to receive sham treatment, the same procedure was performed but no microwave energy was applied. A customized sham program was run on the computer to give a simulated treatment display on the visual display unit. P a tients were evaluated at 12 and 26 weeks after treatment. I f a sham treated patient did not experience improvement at 3 months, a second real transurethral microwave thermother apy was administered if requested.
The questionnaire was designed specifically to assess qual ity of life in patients with B P H under treatment and it covers several dimensions (see Appendix). The 36-itemquestionnaire assesses acceptability (12 items), daily activi ties (6), psychological well-being (8), social activities (6) and overall improvement. Our questionnaire is composed of qual ity of life questionnaire currently in evaluation in other studies.
The questionnaire was designed to assess changes in sex ual function after thermo therapy and it encompasses the following items: 1) do you have a partner (yes/no), 2) do you have sexual intercourse (yes/no), 3) the quality of sexual intercourse (good/bad), 4) do you have an orgasm (yes/no), 5) do you have an ejaculation (yes/no) and 6) do you experience pain during intercourse (yes/no).
Cronbach's a was used to measure internal consistency of the Madsen symptom score items and overall score of ques tions related to quality of life. Correlations between total scores were calculated using the Spearman rank correlation test. The Student t test was used at each point of meas urement to test statistically significant differences between the 2 groups in changes after treatment (clinical parameters, quality of life and Madsen symptom score variables). Single item differences between groups were tested for statistical significance using the chi-square test and 2-sided Fish e r's exact test for 2 X 2 tables.
RESULTS
Mean patient age was 63.3 years (range 50.4 to 78.4). O f 50 patients randomized 47 could be included for evaluation. One patient refused treatment and 2 had incomplete data. A t baseline there were no statistically significant differences between either group for a ll parameter (see table) . A previous analysis showed significant difference in efficacy parameters between the 2 groups in favor of transurethral microwave thermotherapy, 11 In our study patients were excluded for evaluation i f they opted for transurethral microwave thermo therapy treatm ent at 3 months of foliowup (failure of treatment, 15 cases) or refused further folio wup for personal reasons. Exclusion rate for the entire group was 17 and 20 at 12 and 26 weeks, respectively, resulting in a complete data set in 47, 47 and 30 patients at baseline, 12 and 26 weeks followup, respectively. Exclusion rate at 26 weeks was significantly higher in the sham group (13) compared to the transurethral microwave thermotherapy group (7) (chi square test, p = 0.03). number of cases (up to 5% ) 1 item was missing from a total score at a certain point of measurement. Missing items were considered to be random and, consequently, they were completed w ith the mean of the known items when we con structed the overall scores. The standardized Cronbach a of a ll quality of life questionnaire scores ranged from 0.74 to 0.88 and was not improved i f items were deleted, indicating internal consistency of scores was good. There appeared to be a considerable number of dropouts. To overcome this problem an analysis was carried out accord ing to last observation carried forward. Missing data at fol io wup were replaced by last known value during followup. We observed improvement after screening. This method pre sumes th at patients who are lost to followup do not worsen when compared to the last followup, and so this method may underestimate possible further improvement.
Results of the total score of quality of life measures eval uated at baseline, 12 weeks and 26 weeks are presented in the table. No statistically significant differences were found at baseline for a ll parameters. A t 12-week followup there was a statistically significant difference in improvement of max imum uroflow and Madsen symptom score between both groups. No statistically significant difference was observed for any overall scores of quality of life measures. At 26 weeks we observed sustained improvement in the aforementioned parameters and a statistically significant difference in qual ity of life concerning acceptance of voiding problems by the transurethral microwave thermotherapy group.
Sexual function. A t baseline 40 patients (86%) had a steady partner, 91% were s till sexually active and 60% graded their sexual activity as satisfying. A n orgasm could be reached by 92%, 97% had antegrade ejaculation and 14% experienced pain during intercourse. A t baseline and after 26 weeks no statistically significant difference was observed between the two groups for quality of life measures documenting sexual function. No significant differences were found in sexual func tion changes between the 2 treatment options. However, almost 20% of patients treated by either transurethral microwave ther motherapy or sham claimed at 26 weeks after treatment that treatment had influenced sexual function. Change in sexual function was not reflected in responses documented in the post therapy questionnaire, with 21% of patients grading sexual function as satisfying and 26% as dissatisfying. Sexual activi ties at 26-week followup were more or less unchanged when compared to baseline. Overall 86% of patients reported having orgasms and 89% documented having an antegrade ejaculation. No changes were found with respect to discomfort during inter course.
DISCUSSION
Treatm ent of B P H has been redefined during the last de cade because of extensive investigation of alternative treat ments. Several factors have modified general treatment pat terns, including recognition of risk and lim itations of prostatectomy, acceptance of medical therapies, development of m inim ally invasive treatm ent alternatives and progress in understanding appropriate indications for intervention. Since B P H is rarely a life threatening condition, therapy aims to improve quality of life by relieving bothersome u ri nary symptoms.
In our study at every point of followup we found significant differences in improvement of voiding parameters and symp tom scores in favor of the transurethral microwave thermo therapy group. Improvement was not reflected in changes in quality of life measures. A t 12-week followup no differences were found for any of the parameters w hile at 26 weeks only a significant difference was found for acceptance of voiding problems.
One explanation for these findings is that maybe the qual ity of life questionnaire is not disease specific. W hen this study was conducted (1991 to 1992) no validated quality of life questionnaires were available for B P H . Consequently the questionnaire used was extrapolated from other question naires available at that time. Currently we lack a validated quality of life questionnaire. Several groups are evaluating and validating quality of life questionnaires.12 Another rea son for the poor quality of life results could be discrepancy between statistical significance and clinical significance. A l though in our study a statistically significant difference in improvement of objective and subjective parameters was seen between the 2 groups, the clinical difference may be less significant. However, improvement in uroflow was higher in the transurethral microwave thermotherapy group and ab solute improvement was on average in the range of 3 to 4 ml. per second. Also, the decrease in symptom score was signif icantly better for the transurethral microwave thermother apy group when compared to the sham group. Therefore, this argument is not valid to explain the difference.
Severity of symptoms alone does not predict health care seeking behavior14 while increased bother is predictive of health care seeking behavior.13 Because worry and embar rassment about urinary functions are relevant quality of life issues, together w ith u rin ary symptoms and psychological state, it is obvious that these may be important determinants in health care seeking behavior among men with B P H . Maybe symptom scores and quality of life questionnaires measure completely different aspects of the disease, thus explaining the discrepancy between changes in symptoms and quality of life. In other words, if a patient experiences an increase in flow rate w ith persisting nocturia, this w ill lead to a decrease in symptoms but the nocturia may still bother him significantly, resulting in no changes in quality of life, In another case one may find that no significant changes in the m ajority of symptoms occurs but a minimal decrease in fre quency of voiding may already result in significant improve ment in quality of life. Data to support this finding are limited. U n til now only a few studies presented results of studies that included quality of life questionnaires. The way in which quality of life is adversely affected by B P H has also been studied by Tsang and G arraw ay.1^ These authors dem onstrated that symptoms of B P H are associated with restric tions in activities of daily living, including sleeping, driving, playing outdoor sports, and visiting the cinema and theatre.
However, impairment of quality of life by B P H alone is not enough to induce many affected individuals to seek health care. The 2 other factors that may also be important are worry and embarrassment about urinary tract functions. These factors were not included in questionnaires in our study and, therefore, cannot be addressed. Because the ques tionnaire is used to document changes, application of higher energy thermotherapy levels may result in better objective and/or subjective outcome and more significant improvement in quality of life . 15 An increasing number of younger, less symptomatic and sexually active patients seek medical help because of voiding dysfunction. Few scales currently used in B P H research take sexuality into account, probably because B P H in itself does not affect sexuality of patients. However, the International Continence Society B P H study showed that sexual activities of patients frequently were spoiled by voiding problems.12 Nevertheless sexuality is indeed an essential component of quality of life in male patients. Given the fact that the ma jo rity of patients seeking medical treatment are sexually active, the impact of B P H treatments on sexuality should be integrated into a ll disease specific outcome measures. W h at is the effect of surgical therapy on sexual function? According to Montgomery et al a considerable number of urologists are not documenting w ell enough their counseling of men undergoing prostatectomy.16 W e agree that sexually active men should be counseled about risk of ejaculatory disruption and that such counsel should be documented in patient notes. It would seem wise to warn sexually active men that there may be a slight risk of erectile dysfunction.
Data on the effect of transurethral microwave thermother apy on sexual function are minimal.10 In our study no major changes in sexual function were observed. Although a signif icant number of patients mentioned changes in sexual func tion, no significant difference was found between either group. Therefore, we conclude that lower energy thermother apy (software version 2.0) does not significantly change sex ual function. Obviously this statement does not hold for the individual patient.
CONCLUSIONS
Significant changes in objective and subjective parameters are found in patients after lower energy transurethral micro wave thermotherapy. Pio we ver, changes in quality of life measures are minimal and limited to improvement in accept ab ility measures only. The minimal invasiveness of this ther apy, especially preservation of sexual function, is appealing. APPENDIX This is a translation of the Quality of Life questionnaire used for our study. This is not a validated questionnaire. We evaluated the overall score of different subgroups to study differences between the 2 groups. A ll answers were adjusted in the evaluation so that the lower the score, the less severe the complaint. Questions for which the patient could fill in a number were omitted from the evaluation.
